{"id":15360,"date":"2024-10-03T09:29:07","date_gmt":"2024-10-03T09:29:07","guid":{"rendered":"https:\/\/popularreads.co\/smt-completes-enrollment-in-multivessel-talent-trial-for-supraflex-cruz-stent\/"},"modified":"2024-10-03T09:29:07","modified_gmt":"2024-10-03T09:29:07","slug":"smt-completes-enrollment-in-multivessel-talent-trial-for-supraflex-cruz-stent","status":"publish","type":"post","link":"https:\/\/popularreads.co\/?p=15360","title":{"rendered":"SMT Completes Enrollment in Multivessel TALENT Trial for Supraflex Cruz Stent"},"content":{"rendered":"<div class='booster-block booster-read-block'>\n                <div class=\"twp-read-time\">\n                \t<i class=\"booster-icon twp-clock\"><\/i> <span>Read Time:<\/span>3 Minute, 18 Second                <\/div>\n\n            <\/div><p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>Mumbai, India| Oct 3, 2024<\/strong><\/span><\/span><\/p>\n<p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Sahajanand Medical Technologies (SMT) is excited to announce the successful completion of patient enrollment in the\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>Multivessel TALENT trial<\/strong><\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">, a cutting-edge study comparing SMT\u2019s\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>Supraflex Cruz<\/strong><\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> stent with the SYNERGY stent in patients with complex three-vessel coronary artery disease (3VD).<\/span><\/span><\/p>\n<p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Led by\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>Professor Patrick W. Serruys<\/strong><\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> and conducted by the\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>CORRIB Research Centre<\/strong><\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> at the\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>National University of Ireland, Galway<\/strong><\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">, the trial enrolled 1,550 patients across Europe. The\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>Multivessel TALENT trial<\/strong><\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> is one of the most advanced trials of its kind, incorporating\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>state-of-the-art PCI best practices<\/strong><\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> such as:<\/span><\/span><\/p>\n<ul>\n<li style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">100% use of\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">quantitative flow ratio (QFR)<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> for physiological lesion assessment.<\/span><\/span><\/li>\n<li style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">IVUS<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> or\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">OCT<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">-guided lesion optimization to ensure the best possible outcomes.<\/span><\/span><\/li>\n<li style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">1-month dual antiplatelet therapy (DAPT)<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> followed by single antiplatelet therapy using\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">prasugrel<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> as the antiplatelet of choice.<\/span><\/span><\/li>\n<\/ul>\n<p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Both\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">Supraflex Cruz<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> and SYNERGY stents were selected for this trial based on their\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">best-in-class performance<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">, as evidenced by recent clinical trials. Supraflex Cruz, in particular, has demonstrated superior outcomes in complex lesions, including bifurcations, and\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">high bleeding risk (HBR) patients<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">, supported by data from the\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">FIRE trial<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> and\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">COMPARE 60\/80<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">.<\/span><\/span><\/p>\n<p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>Key Features of Supraflex Cruz<\/strong><\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"><strong>:<\/strong><\/span><\/span><\/p>\n<ul>\n<li style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">Low trackability force<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> and\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">best-in-class overexpansion capacity<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> make it ideal for treating complex PCI cases.<\/span><\/span><\/li>\n<li style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Its design facilitates\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">easy access to side branches<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">, ensuring optimal treatment of bifurcation lesions.<\/span><\/span><\/li>\n<li style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Proven\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">rapid endothelialization<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> (91% at 35 days, almost complete at 6 months).<\/span><\/span><\/li>\n<li style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt;font-style:normal;font-variant:normal;font-weight:400;list-style-type:disc;text-decoration:none;vertical-align:baseline\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Excellent performance in\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">1-month DAPT<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> protocols, showing\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">high efficacy<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> and\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">low bleeding<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> risk in HBR patients.<\/span><\/span><\/li>\n<\/ul>\n<p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">The\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\">Multivessel TALENT trial<\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> will further validate Supraflex Cruz\u2019s superior capabilities in addressing some of the most challenging coronary conditions.<\/span><\/span><\/p>\n<p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Professor Serruys, the Chair and Chief Investigator of the trial, commented, \u201cWe designed this important study to compare the SUPRAFLEX Cruz family of stents to the SYNERGY stent applying \u201cbest practice\u201d treatment principles for PCI including the Syntax II score recommendation, QFR guidance for physiology, imaging guidance for optimal stent deployment, contemporary CTO techniques and optimal medical therapy in patients with 3-vessel coronary disease. We are very pleased that enrolment is now complete and look forward to reporting the primary endpoint results in late 2025.\u201d<\/span><\/span><\/p>\n<p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Dr. Krishna Sudhir, Chief Medical Officer of SMT remarked, \u201cThis important trial will add to the literature on PCI in complex (3-vessel) coronary artery disease by evaluating SMT\u2019s Supraflex Cruz against Boston Scientific Synergy, in the setting of 1-month of dual antiplatelet therapy. We congratulate Professor Serruys and his team at CORRIB Research Center and the National University of Ireland at Galway on their remarkable efforts to enroll 1550 patients in a timely fashion, and we look forward to presentation of the trial outcomes at the 1-year follow up.\u00a0<\/span><\/span><\/p>\n<p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\">\u00a0<\/p>\n<p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Synergy is a trademark stent of Boston Scientific Corporation.\u00a0<\/span><\/span><\/p>\n<p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>About SMT (Sahajanand Medical Technologies)<\/strong><\/span><\/span><br \/><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">SMT is a global leader in cardiovascular medical devices, specializing in drug-eluting stents and structural heart disease solutions. Operating in over 80 countries, SMT is dedicated to advancing patient care through innovative medical technologies and clinical excellence, as demonstrated by the\u00a0<\/span><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>Multivessel TALENT trial<\/strong><\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">. SMT has achieved recognitions from the Ministry of Health Sciences &amp; Technologies for its tremendous contributions in the field of coronary healthcare. SMT also pioneered the introduction of biodegradable polymers in the cardiovascular segment.<\/span><\/span><\/p>\n<p style=\"line-height:1.295;margin-bottom:8pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>About Supraflex Cruz<\/strong><\/span><\/span><\/p>\n<p style=\"line-height:1.2;margin-bottom:0pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">The Cruz design provides physicians access to difficult and tortuous lesions which are particularly challenging in their practice. The stent retains all the benefits of Supraflex stents or the previous \u201cSupra\u201d family of stents, viz, thin struts, a blend of proprietary biodegradable polymers to release the drug, high radial strength, and low crossing profile. Supraflex Cruz has a large and extensive size matrix, covering diameters from 2.0 to 4.5 and lengths from 8 mm to 48 mm. This size matrix ensures no compromises in the coronaries for either physician or patient.<\/span><\/span><\/p>\n<p style=\"line-height:1.2;margin-bottom:0pt;margin-top:0pt\" dir=\"ltr\">\u00a0<\/p>\n<p style=\"line-height:1.2;margin-bottom:0pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;text-decoration:none;vertical-align:baseline\"><strong>Media Contact<\/strong><\/span><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">:\u00a0<\/span><\/span><\/p>\n<p style=\"line-height:1.2;margin-bottom:0pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Tejaswini Kamalkar\u00a0<\/span><\/span><\/p>\n<p style=\"line-height:1.2;margin-bottom:0pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Sr Manager\u00a0<\/span><\/span><\/p>\n<p style=\"line-height:1.2;margin-bottom:0pt;margin-top:0pt\" dir=\"ltr\"><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">Corporate Communications\u00a0<\/span><\/span><\/p>\n<p style=\"line-height:1.2;margin-bottom:0pt;margin-top:0pt\" dir=\"ltr\"><a style=\"text-decoration:none\" href=\"mailto:tejaswini.kamalkar@smt.in\"><span style=\"background-color:transparent;color:#467886;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;vertical-align:baseline\"><u>tejaswini.kamalkar@smt.in<\/u><\/span><\/span><\/a><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\">\u00a0<\/span><\/span><\/p>\n<p style=\"line-height:1.2;margin-bottom:0pt;margin-top:0pt\" dir=\"ltr\"><a style=\"text-decoration:none\" href=\"http:\/\/www.smtpl.in\"><span style=\"background-color:transparent;color:#467886;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;vertical-align:baseline\"><u>www.smtpl.in<\/u><\/span><\/span><\/a><span style=\"background-color:transparent;color:#000000;font-family:Cambria, serif;font-size:12pt\"><span style=\"font-style:normal;font-variant:normal;font-weight:400;text-decoration:none;vertical-align:baseline\"> \u00a0<\/span><\/span><\/p>\n        <div class=\"booster-block booster-reactions-block\">\n            <div class=\"twp-reactions-icons\">\n                \n                <div class=\"twp-reacts-wrap\">\n                    <a react-data=\"be-react-1\" post-id=\"15360\" class=\"be-face-icons un-reacted\" href=\"javascript:void(0)\">\n                        <img decoding=\"async\" src=\"https:\/\/popularreads.co\/wp-content\/plugins\/booster-extension\/\/assets\/icon\/happy.svg\" alt=\"Happy\">\n                    <\/a>\n                    <div class=\"twp-reaction-title\">\n                        Happy                    <\/div>\n                    <div class=\"twp-count-percent\">\n                                                    <span style=\"display: none;\" class=\"twp-react-count\">0<\/span>\n                        \n                                                <span class=\"twp-react-percent\"><span>0<\/span> %<\/span>\n                                            <\/div>\n                <\/div>\n\n                <div class=\"twp-reacts-wrap\">\n                    <a react-data=\"be-react-2\" post-id=\"15360\" class=\"be-face-icons un-reacted\" href=\"javascript:void(0)\">\n                        <img decoding=\"async\" src=\"https:\/\/popularreads.co\/wp-content\/plugins\/booster-extension\/\/assets\/icon\/sad.svg\" alt=\"Sad\">\n                    <\/a>\n                    <div class=\"twp-reaction-title\">\n                        Sad                    <\/div>\n                    <div class=\"twp-count-percent\">\n                                                    <span style=\"display: none;\" class=\"twp-react-count\">0<\/span>\n                                                                        <span class=\"twp-react-percent\"><span>0<\/span> %<\/span>\n                                            <\/div>\n                <\/div>\n\n                <div class=\"twp-reacts-wrap\">\n                    <a react-data=\"be-react-3\" post-id=\"15360\" class=\"be-face-icons un-reacted\" href=\"javascript:void(0)\">\n                        <img decoding=\"async\" src=\"https:\/\/popularreads.co\/wp-content\/plugins\/booster-extension\/\/assets\/icon\/excited.svg\" alt=\"Excited\">\n                    <\/a>\n                    <div class=\"twp-reaction-title\">\n                        Excited                    <\/div>\n                    <div class=\"twp-count-percent\">\n                                                    <span style=\"display: none;\" class=\"twp-react-count\">0<\/span>\n                                                                        <span class=\"twp-react-percent\"><span>0<\/span> %<\/span>\n                                            <\/div>\n                <\/div>\n\n                <div class=\"twp-reacts-wrap\">\n                    <a react-data=\"be-react-6\" post-id=\"15360\" class=\"be-face-icons un-reacted\" href=\"javascript:void(0)\">\n                        <img decoding=\"async\" src=\"https:\/\/popularreads.co\/wp-content\/plugins\/booster-extension\/\/assets\/icon\/sleepy.svg\" alt=\"Sleepy\">\n                    <\/a>\n                    <div class=\"twp-reaction-title\">\n                        Sleepy                    <\/div>\n                    <div class=\"twp-count-percent\">\n                                                    <span style=\"display: none;\" class=\"twp-react-count\">0<\/span>\n                        \n                                                <span class=\"twp-react-percent\"><span>0<\/span> %<\/span>\n                                            <\/div>\n                <\/div>\n\n                <div class=\"twp-reacts-wrap\">\n                    <a react-data=\"be-react-4\" post-id=\"15360\" class=\"be-face-icons un-reacted\" href=\"javascript:void(0)\">\n                        <img decoding=\"async\" src=\"https:\/\/popularreads.co\/wp-content\/plugins\/booster-extension\/\/assets\/icon\/angry.svg\" alt=\"Angry\">\n                    <\/a>\n                    <div class=\"twp-reaction-title\">Angry<\/div>\n                    <div class=\"twp-count-percent\">\n                                                    <span style=\"display: none;\" class=\"twp-react-count\">0<\/span>\n                                                                        <span class=\"twp-react-percent\"><span>0<\/span> %<\/span>\n                        \n                    <\/div>\n                <\/div>\n\n                <div class=\"twp-reacts-wrap\">\n                    <a react-data=\"be-react-5\" post-id=\"15360\" class=\"be-face-icons un-reacted\" href=\"javascript:void(0)\">\n                        <img decoding=\"async\" src=\"https:\/\/popularreads.co\/wp-content\/plugins\/booster-extension\/\/assets\/icon\/surprise.svg\" alt=\"Surprise\">\n                    <\/a>\n                    <div class=\"twp-reaction-title\">Surprise<\/div>\n                    <div class=\"twp-count-percent\">\n                                                    <span style=\"display: none;\" class=\"twp-react-count\">0<\/span>\n                                                                        <span class=\"twp-react-percent\"><span>0<\/span> %<\/span>\n                                            <\/div>\n                <\/div>\n\n            <\/div>\n        <\/div>\n\n    ","protected":false},"excerpt":{"rendered":"<p>Mumbai, India| Oct 3, 2024 Sahajanand Medical Technologies (SMT) is excited to announce the successful completion of patient enrollment in the\u00a0Multivessel TALENT trial, a cutting-edge study comparing SMT\u2019s\u00a0Supraflex Cruz stent with the SYNERGY stent in patients with complex three-vessel coronary artery disease (3VD). Led by\u00a0Professor Patrick W. Serruys and conducted by the\u00a0CORRIB Research Centre at [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":15361,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[66],"tags":[],"class_list":["post-15360","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-agency-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SMT Completes Enrollment in Multivessel TALENT Trial for Supraflex Cruz Stent<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/popularreads.co\/?p=15360\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SMT Completes Enrollment in Multivessel TALENT Trial for Supraflex Cruz Stent\" \/>\n<meta property=\"og:description\" content=\"Mumbai, India| Oct 3, 2024 Sahajanand Medical Technologies (SMT) is excited to announce the successful completion of patient enrollment in the\u00a0Multivessel TALENT trial, a cutting-edge study comparing SMT\u2019s\u00a0Supraflex Cruz stent with the SYNERGY stent in patients with complex three-vessel coronary artery disease (3VD). Led by\u00a0Professor Patrick W. Serruys and conducted by the\u00a0CORRIB Research Centre at [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/popularreads.co\/?p=15360\" \/>\n<meta property=\"og:site_name\" content=\"Popular Reads\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-03T09:29:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/popularreads.co\/wp-content\/uploads\/2024\/10\/172794774894777448055.1727930988415_content_img.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1942\" \/>\n\t<meta property=\"og:image:height\" content=\"407\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/popularreads.co\\\/?p=15360#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/popularreads.co\\\/?p=15360\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/popularreads.co\\\/#\\\/schema\\\/person\\\/9e92abcc10fa4f78227517a6782ef83c\"},\"headline\":\"SMT Completes Enrollment in Multivessel TALENT Trial for Supraflex Cruz Stent\",\"datePublished\":\"2024-10-03T09:29:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/popularreads.co\\\/?p=15360\"},\"wordCount\":640,\"publisher\":{\"@id\":\"https:\\\/\\\/popularreads.co\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/popularreads.co\\\/?p=15360#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/popularreads.co\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/172794774894777448055.1727930988415_content_img.jpeg\",\"articleSection\":[\"Agency News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/popularreads.co\\\/?p=15360\",\"url\":\"https:\\\/\\\/popularreads.co\\\/?p=15360\",\"name\":\"SMT Completes Enrollment in Multivessel TALENT Trial for Supraflex Cruz Stent\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/popularreads.co\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/popularreads.co\\\/?p=15360#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/popularreads.co\\\/?p=15360#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/popularreads.co\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/172794774894777448055.1727930988415_content_img.jpeg\",\"datePublished\":\"2024-10-03T09:29:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/popularreads.co\\\/?p=15360#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/popularreads.co\\\/?p=15360\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/popularreads.co\\\/?p=15360#primaryimage\",\"url\":\"https:\\\/\\\/popularreads.co\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/172794774894777448055.1727930988415_content_img.jpeg\",\"contentUrl\":\"https:\\\/\\\/popularreads.co\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/172794774894777448055.1727930988415_content_img.jpeg\",\"width\":1942,\"height\":407},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/popularreads.co\\\/?p=15360#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/popularreads.co\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SMT Completes Enrollment in Multivessel TALENT Trial for Supraflex Cruz Stent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/popularreads.co\\\/#website\",\"url\":\"https:\\\/\\\/popularreads.co\\\/\",\"name\":\"Popular Reads\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/popularreads.co\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/popularreads.co\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/popularreads.co\\\/#organization\",\"name\":\"Popular Reads\",\"url\":\"https:\\\/\\\/popularreads.co\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/popularreads.co\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/popularreads.co\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/Popular-Reads_Logo_Design-300.png\",\"contentUrl\":\"https:\\\/\\\/popularreads.co\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/Popular-Reads_Logo_Design-300.png\",\"width\":300,\"height\":80,\"caption\":\"Popular Reads\"},\"image\":{\"@id\":\"https:\\\/\\\/popularreads.co\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/popularreads.co\\\/#\\\/schema\\\/person\\\/9e92abcc10fa4f78227517a6782ef83c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a6be411a6d0f7b01ba2c4803c9a00e5f9b7217beca69d3196391be82ee712ac1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a6be411a6d0f7b01ba2c4803c9a00e5f9b7217beca69d3196391be82ee712ac1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a6be411a6d0f7b01ba2c4803c9a00e5f9b7217beca69d3196391be82ee712ac1?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/popularreads.co\"],\"url\":\"https:\\\/\\\/popularreads.co\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SMT Completes Enrollment in Multivessel TALENT Trial for Supraflex Cruz Stent","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/popularreads.co\/?p=15360","og_locale":"en_US","og_type":"article","og_title":"SMT Completes Enrollment in Multivessel TALENT Trial for Supraflex Cruz Stent","og_description":"Mumbai, India| Oct 3, 2024 Sahajanand Medical Technologies (SMT) is excited to announce the successful completion of patient enrollment in the\u00a0Multivessel TALENT trial, a cutting-edge study comparing SMT\u2019s\u00a0Supraflex Cruz stent with the SYNERGY stent in patients with complex three-vessel coronary artery disease (3VD). Led by\u00a0Professor Patrick W. Serruys and conducted by the\u00a0CORRIB Research Centre at [&hellip;]","og_url":"https:\/\/popularreads.co\/?p=15360","og_site_name":"Popular Reads","article_published_time":"2024-10-03T09:29:07+00:00","og_image":[{"width":1942,"height":407,"url":"https:\/\/popularreads.co\/wp-content\/uploads\/2024\/10\/172794774894777448055.1727930988415_content_img.jpeg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/popularreads.co\/?p=15360#article","isPartOf":{"@id":"https:\/\/popularreads.co\/?p=15360"},"author":{"name":"admin","@id":"https:\/\/popularreads.co\/#\/schema\/person\/9e92abcc10fa4f78227517a6782ef83c"},"headline":"SMT Completes Enrollment in Multivessel TALENT Trial for Supraflex Cruz Stent","datePublished":"2024-10-03T09:29:07+00:00","mainEntityOfPage":{"@id":"https:\/\/popularreads.co\/?p=15360"},"wordCount":640,"publisher":{"@id":"https:\/\/popularreads.co\/#organization"},"image":{"@id":"https:\/\/popularreads.co\/?p=15360#primaryimage"},"thumbnailUrl":"https:\/\/popularreads.co\/wp-content\/uploads\/2024\/10\/172794774894777448055.1727930988415_content_img.jpeg","articleSection":["Agency News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/popularreads.co\/?p=15360","url":"https:\/\/popularreads.co\/?p=15360","name":"SMT Completes Enrollment in Multivessel TALENT Trial for Supraflex Cruz Stent","isPartOf":{"@id":"https:\/\/popularreads.co\/#website"},"primaryImageOfPage":{"@id":"https:\/\/popularreads.co\/?p=15360#primaryimage"},"image":{"@id":"https:\/\/popularreads.co\/?p=15360#primaryimage"},"thumbnailUrl":"https:\/\/popularreads.co\/wp-content\/uploads\/2024\/10\/172794774894777448055.1727930988415_content_img.jpeg","datePublished":"2024-10-03T09:29:07+00:00","breadcrumb":{"@id":"https:\/\/popularreads.co\/?p=15360#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/popularreads.co\/?p=15360"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/popularreads.co\/?p=15360#primaryimage","url":"https:\/\/popularreads.co\/wp-content\/uploads\/2024\/10\/172794774894777448055.1727930988415_content_img.jpeg","contentUrl":"https:\/\/popularreads.co\/wp-content\/uploads\/2024\/10\/172794774894777448055.1727930988415_content_img.jpeg","width":1942,"height":407},{"@type":"BreadcrumbList","@id":"https:\/\/popularreads.co\/?p=15360#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/popularreads.co\/"},{"@type":"ListItem","position":2,"name":"SMT Completes Enrollment in Multivessel TALENT Trial for Supraflex Cruz Stent"}]},{"@type":"WebSite","@id":"https:\/\/popularreads.co\/#website","url":"https:\/\/popularreads.co\/","name":"Popular Reads","description":"","publisher":{"@id":"https:\/\/popularreads.co\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/popularreads.co\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/popularreads.co\/#organization","name":"Popular Reads","url":"https:\/\/popularreads.co\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/popularreads.co\/#\/schema\/logo\/image\/","url":"https:\/\/popularreads.co\/wp-content\/uploads\/2022\/04\/Popular-Reads_Logo_Design-300.png","contentUrl":"https:\/\/popularreads.co\/wp-content\/uploads\/2022\/04\/Popular-Reads_Logo_Design-300.png","width":300,"height":80,"caption":"Popular Reads"},"image":{"@id":"https:\/\/popularreads.co\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/popularreads.co\/#\/schema\/person\/9e92abcc10fa4f78227517a6782ef83c","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a6be411a6d0f7b01ba2c4803c9a00e5f9b7217beca69d3196391be82ee712ac1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a6be411a6d0f7b01ba2c4803c9a00e5f9b7217beca69d3196391be82ee712ac1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a6be411a6d0f7b01ba2c4803c9a00e5f9b7217beca69d3196391be82ee712ac1?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/popularreads.co"],"url":"https:\/\/popularreads.co\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/popularreads.co\/index.php?rest_route=\/wp\/v2\/posts\/15360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/popularreads.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/popularreads.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/popularreads.co\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/popularreads.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15360"}],"version-history":[{"count":0,"href":"https:\/\/popularreads.co\/index.php?rest_route=\/wp\/v2\/posts\/15360\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/popularreads.co\/index.php?rest_route=\/wp\/v2\/media\/15361"}],"wp:attachment":[{"href":"https:\/\/popularreads.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/popularreads.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/popularreads.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}